nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—PDGFRA—brain cancer	0.363	0.664	CbGaD
Regorafenib—CYP2C9—brain cancer	0.184	0.337	CbGaD
Regorafenib—UGT1A1—Etoposide—brain cancer	0.0374	0.257	CbGbCtD
Regorafenib—ABCG2—Carboplatin—brain cancer	0.0245	0.169	CbGbCtD
Regorafenib—CYP3A4—Temozolomide—brain cancer	0.0216	0.149	CbGbCtD
Regorafenib—ABCG2—Etoposide—brain cancer	0.0206	0.142	CbGbCtD
Regorafenib—CYP3A4—Lomustine—brain cancer	0.0184	0.127	CbGbCtD
Regorafenib—CYP2C8—Etoposide—brain cancer	0.011	0.0754	CbGbCtD
Regorafenib—ABCB1—Etoposide—brain cancer	0.00742	0.051	CbGbCtD
Regorafenib—CYP3A4—Etoposide—brain cancer	0.00445	0.0306	CbGbCtD
Regorafenib—FGFR2—skull—brain cancer	0.00288	0.0361	CbGeAlD
Regorafenib—Sorafenib—PDGFRA—brain cancer	0.00253	0.663	CrCbGaD
Regorafenib—Hepatotoxicity—Lomustine—brain cancer	0.00216	0.0276	CcSEcCtD
Regorafenib—Traumatic liver injury—Temozolomide—brain cancer	0.00172	0.022	CcSEcCtD
Regorafenib—FLT4—endothelium—brain cancer	0.00154	0.0193	CbGeAlD
Regorafenib—Neoplasm—Lomustine—brain cancer	0.0015	0.0193	CcSEcCtD
Regorafenib—Mucosal inflammation—Hydroxyurea—brain cancer	0.00148	0.0189	CcSEcCtD
Regorafenib—FLT4—blood vessel—brain cancer	0.00142	0.0178	CbGeAlD
Regorafenib—Hypomagnesaemia—Hydroxyurea—brain cancer	0.00129	0.0165	CcSEcCtD
Regorafenib—Dysphonia—Procarbazine—brain cancer	0.00128	0.0165	CcSEcCtD
Regorafenib—Sorafenib—CYP2C9—brain cancer	0.00128	0.336	CrCbGaD
Regorafenib—Lymphopenia—Temozolomide—brain cancer	0.00125	0.016	CcSEcCtD
Regorafenib—TEK—endothelium—brain cancer	0.00124	0.0155	CbGeAlD
Regorafenib—FLT1—endothelium—brain cancer	0.0012	0.015	CbGeAlD
Regorafenib—EPHA2—blood vessel—brain cancer	0.00117	0.0147	CbGeAlD
Regorafenib—TEK—blood vessel—brain cancer	0.00114	0.0143	CbGeAlD
Regorafenib—FGFR2—hindbrain—brain cancer	0.00114	0.0143	CbGeAlD
Regorafenib—FLT1—blood vessel—brain cancer	0.0011	0.0139	CbGeAlD
Regorafenib—NTRK1—midbrain—brain cancer	0.00109	0.0137	CbGeAlD
Regorafenib—MAPK11—telencephalon—brain cancer	0.00107	0.0135	CbGeAlD
Regorafenib—Hepatotoxicity—Hydroxyurea—brain cancer	0.00106	0.0136	CcSEcCtD
Regorafenib—FRK—gonad—brain cancer	0.00105	0.0132	CbGeAlD
Regorafenib—RAF1—hindbrain—brain cancer	0.00105	0.0131	CbGeAlD
Regorafenib—KDR—endothelium—brain cancer	0.00101	0.0127	CbGeAlD
Regorafenib—Cyst—Carmustine—brain cancer	0.000989	0.0127	CcSEcCtD
Regorafenib—KDR—blood vessel—brain cancer	0.000934	0.0117	CbGeAlD
Regorafenib—Mucosal inflammation—Etoposide—brain cancer	0.000923	0.0118	CcSEcCtD
Regorafenib—DDR2—pituitary gland—brain cancer	0.000921	0.0116	CbGeAlD
Regorafenib—Stomatitis—Lomustine—brain cancer	0.000908	0.0116	CcSEcCtD
Regorafenib—KIT—endothelium—brain cancer	0.000898	0.0113	CbGeAlD
Regorafenib—Hyperuricaemia—Hydroxyurea—brain cancer	0.000882	0.0113	CcSEcCtD
Regorafenib—Hepatotoxicity—Carmustine—brain cancer	0.000856	0.011	CcSEcCtD
Regorafenib—Haemoglobin—Lomustine—brain cancer	0.00084	0.0108	CcSEcCtD
Regorafenib—Haemorrhage—Lomustine—brain cancer	0.000836	0.0107	CcSEcCtD
Regorafenib—Blood uric acid increased—Hydroxyurea—brain cancer	0.000833	0.0107	CcSEcCtD
Regorafenib—KIT—blood vessel—brain cancer	0.000828	0.0104	CbGeAlD
Regorafenib—Hepatotoxicity—Temozolomide—brain cancer	0.000827	0.0106	CcSEcCtD
Regorafenib—PDGFRB—blood vessel—brain cancer	0.000808	0.0101	CbGeAlD
Regorafenib—FRK—endocrine gland—brain cancer	0.000796	0.00998	CbGeAlD
Regorafenib—DDR2—spinal cord—brain cancer	0.000793	0.00994	CbGeAlD
Regorafenib—KIT—hindbrain—brain cancer	0.000789	0.0099	CbGeAlD
Regorafenib—Nail disorder—Etoposide—brain cancer	0.000788	0.0101	CcSEcCtD
Regorafenib—Endocrine disorder—Temozolomide—brain cancer	0.000771	0.00988	CcSEcCtD
Regorafenib—Liver injury—Temozolomide—brain cancer	0.000759	0.00973	CcSEcCtD
Regorafenib—Neoplasm—Hydroxyurea—brain cancer	0.000739	0.00947	CcSEcCtD
Regorafenib—Alopecia—Lomustine—brain cancer	0.000739	0.00946	CcSEcCtD
Regorafenib—DDR2—endocrine gland—brain cancer	0.000714	0.00895	CbGeAlD
Regorafenib—DDR2—head—brain cancer	0.000705	0.00884	CbGeAlD
Regorafenib—Hyperbilirubinaemia—Temozolomide—brain cancer	0.000703	0.009	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Procarbazine—brain cancer	0.000691	0.00885	CcSEcCtD
Regorafenib—ABL1—hindbrain—brain cancer	0.000687	0.00862	CbGeAlD
Regorafenib—FGFR1—telencephalon—brain cancer	0.00068	0.00853	CbGeAlD
Regorafenib—Infection—Carboplatin—brain cancer	0.000674	0.00864	CcSEcCtD
Regorafenib—MAPK11—head—brain cancer	0.000668	0.00838	CbGeAlD
Regorafenib—Hepatotoxicity—Etoposide—brain cancer	0.000662	0.00848	CcSEcCtD
Regorafenib—FGFR2—brainstem—brain cancer	0.000652	0.00817	CbGeAlD
Regorafenib—Leukopenia—Lomustine—brain cancer	0.000651	0.00835	CcSEcCtD
Regorafenib—BRAF—pituitary gland—brain cancer	0.000651	0.00817	CbGeAlD
Regorafenib—DDR2—central nervous system—brain cancer	0.000643	0.00806	CbGeAlD
Regorafenib—DDR2—cerebellum—brain cancer	0.000629	0.00788	CbGeAlD
Regorafenib—EPHX2—pituitary gland—brain cancer	0.000622	0.0078	CbGeAlD
Regorafenib—MAPK11—central nervous system—brain cancer	0.00061	0.00765	CbGeAlD
Regorafenib—RAF1—brainstem—brain cancer	0.0006	0.00753	CbGeAlD
Regorafenib—Neoplasm—Carmustine—brain cancer	0.000598	0.00766	CcSEcCtD
Regorafenib—MAPK11—cerebellum—brain cancer	0.000596	0.00747	CbGeAlD
Regorafenib—Infection—Lomustine—brain cancer	0.00059	0.00756	CcSEcCtD
Regorafenib—Thrombocytopenia—Lomustine—brain cancer	0.000581	0.00745	CcSEcCtD
Regorafenib—Pain—Carboplatin—brain cancer	0.00058	0.00744	CcSEcCtD
Regorafenib—FGFR2—telencephalon—brain cancer	0.000578	0.00725	CbGeAlD
Regorafenib—Neoplasm—Temozolomide—brain cancer	0.000578	0.0074	CcSEcCtD
Regorafenib—Stomatitis—Procarbazine—brain cancer	0.000576	0.00738	CcSEcCtD
Regorafenib—BRAF—midbrain—brain cancer	0.000574	0.0072	CbGeAlD
Regorafenib—TEK—telencephalon—brain cancer	0.000554	0.00695	CbGeAlD
Regorafenib—FGFR1—pituitary gland—brain cancer	0.000554	0.00694	CbGeAlD
Regorafenib—Hyperuricaemia—Etoposide—brain cancer	0.000551	0.00706	CcSEcCtD
Regorafenib—Body temperature increased—Carboplatin—brain cancer	0.000537	0.00688	CcSEcCtD
Regorafenib—FLT1—telencephalon—brain cancer	0.000536	0.00672	CbGeAlD
Regorafenib—FGFR1—medulla oblongata—brain cancer	0.000534	0.0067	CbGeAlD
Regorafenib—Haemoglobin—Procarbazine—brain cancer	0.000533	0.00683	CcSEcCtD
Regorafenib—RAF1—telencephalon—brain cancer	0.000533	0.00668	CbGeAlD
Regorafenib—Haemorrhage—Procarbazine—brain cancer	0.000531	0.0068	CcSEcCtD
Regorafenib—Gastroenteritis—Temozolomide—brain cancer	0.000523	0.0067	CcSEcCtD
Regorafenib—Blood uric acid increased—Etoposide—brain cancer	0.000521	0.00667	CcSEcCtD
Regorafenib—Decreased appetite—Lomustine—brain cancer	0.000516	0.00661	CcSEcCtD
Regorafenib—DDR2—brain—brain cancer	0.000511	0.0064	CbGeAlD
Regorafenib—PDGFRA—telencephalon—brain cancer	0.000502	0.0063	CbGeAlD
Regorafenib—RET—pituitary gland—brain cancer	0.000496	0.00621	CbGeAlD
Regorafenib—FGFR1—midbrain—brain cancer	0.000488	0.00612	CbGeAlD
Regorafenib—MAPK11—brain—brain cancer	0.000484	0.00607	CbGeAlD
Regorafenib—Hyponatraemia—Carmustine—brain cancer	0.000482	0.00617	CcSEcCtD
Regorafenib—Neutropenia—Hydroxyurea—brain cancer	0.00048	0.00615	CcSEcCtD
Regorafenib—RET—medulla oblongata—brain cancer	0.000478	0.006	CbGeAlD
Regorafenib—FGFR1—spinal cord—brain cancer	0.000476	0.00597	CbGeAlD
Regorafenib—Body temperature increased—Lomustine—brain cancer	0.000469	0.00601	CcSEcCtD
Regorafenib—Alopecia—Procarbazine—brain cancer	0.000469	0.00601	CcSEcCtD
Regorafenib—EPHA2—pituitary gland—brain cancer	0.000463	0.0058	CbGeAlD
Regorafenib—Infestation—Hydroxyurea—brain cancer	0.000457	0.00586	CcSEcCtD
Regorafenib—Infestation NOS—Hydroxyurea—brain cancer	0.000457	0.00586	CcSEcCtD
Regorafenib—KIT—brainstem—brain cancer	0.000452	0.00567	CbGeAlD
Regorafenib—TEK—pituitary gland—brain cancer	0.000451	0.00566	CbGeAlD
Regorafenib—FLT1—gonad—brain cancer	0.000447	0.00561	CbGeAlD
Regorafenib—Stomatitis—Hydroxyurea—brain cancer	0.000446	0.00571	CcSEcCtD
Regorafenib—RAF1—gonad—brain cancer	0.000445	0.00558	CbGeAlD
Regorafenib—BRAF—cerebellum—brain cancer	0.000444	0.00557	CbGeAlD
Regorafenib—UGT1A9—endocrine gland—brain cancer	0.000441	0.00553	CbGeAlD
Regorafenib—RET—midbrain—brain cancer	0.000437	0.00548	CbGeAlD
Regorafenib—Hypokalaemia—Carmustine—brain cancer	0.000437	0.0056	CcSEcCtD
Regorafenib—FLT1—pituitary gland—brain cancer	0.000436	0.00547	CbGeAlD
Regorafenib—TEK—medulla oblongata—brain cancer	0.000436	0.00546	CbGeAlD
Regorafenib—FLT4—endocrine gland—brain cancer	0.000435	0.00545	CbGeAlD
Regorafenib—RAF1—pituitary gland—brain cancer	0.000434	0.00544	CbGeAlD
Regorafenib—Tremor—Procarbazine—brain cancer	0.000433	0.00555	CcSEcCtD
Regorafenib—Hepatobiliary disease—Hydroxyurea—brain cancer	0.000433	0.00554	CcSEcCtD
Regorafenib—FLT4—head—brain cancer	0.000429	0.00538	CbGeAlD
Regorafenib—Anaemia—Procarbazine—brain cancer	0.000427	0.00547	CcSEcCtD
Regorafenib—RET—spinal cord—brain cancer	0.000426	0.00535	CbGeAlD
Regorafenib—Dry skin—Temozolomide—brain cancer	0.000425	0.00545	CcSEcCtD
Regorafenib—EPHX2—cerebellum—brain cancer	0.000425	0.00532	CbGeAlD
Regorafenib—Hypokalaemia—Temozolomide—brain cancer	0.000422	0.00541	CcSEcCtD
Regorafenib—FLT1—medulla oblongata—brain cancer	0.000421	0.00528	CbGeAlD
Regorafenib—PDGFRA—gonad—brain cancer	0.000419	0.00526	CbGeAlD
Regorafenib—RAF1—medulla oblongata—brain cancer	0.000419	0.00525	CbGeAlD
Regorafenib—Aspartate aminotransferase increased—Temozolomide—brain cancer	0.000418	0.00535	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Temozolomide—brain cancer	0.000418	0.00535	CcSEcCtD
Regorafenib—Leukopenia—Procarbazine—brain cancer	0.000413	0.0053	CcSEcCtD
Regorafenib—Haemoglobin—Hydroxyurea—brain cancer	0.000413	0.00529	CcSEcCtD
Regorafenib—Haemorrhage—Hydroxyurea—brain cancer	0.000411	0.00526	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Temozolomide—brain cancer	0.000409	0.00524	CcSEcCtD
Regorafenib—FGFR2—spinal cord—brain cancer	0.000405	0.00508	CbGeAlD
Regorafenib—KIT—telencephalon—brain cancer	0.000402	0.00503	CbGeAlD
Regorafenib—Hypertension—Procarbazine—brain cancer	0.000399	0.00511	CcSEcCtD
Regorafenib—TEK—midbrain—brain cancer	0.000398	0.00499	CbGeAlD
Regorafenib—ABL1—brainstem—brain cancer	0.000394	0.00494	CbGeAlD
Regorafenib—PDGFRB—telencephalon—brain cancer	0.000392	0.00492	CbGeAlD
Regorafenib—TEK—spinal cord—brain cancer	0.000388	0.00487	CbGeAlD
Regorafenib—Neutropenia—Carmustine—brain cancer	0.000388	0.00497	CcSEcCtD
Regorafenib—FLT1—midbrain—brain cancer	0.000385	0.00483	CbGeAlD
Regorafenib—Dry mouth—Procarbazine—brain cancer	0.000385	0.00493	CcSEcCtD
Regorafenib—RET—endocrine gland—brain cancer	0.000384	0.00481	CbGeAlD
Regorafenib—RAF1—midbrain—brain cancer	0.000383	0.0048	CbGeAlD
Regorafenib—RET—head—brain cancer	0.000379	0.00475	CbGeAlD
Regorafenib—FGFR1—cerebellum—brain cancer	0.000378	0.00474	CbGeAlD
Regorafenib—Vomiting—Lomustine—brain cancer	0.000378	0.00484	CcSEcCtD
Regorafenib—FLT1—spinal cord—brain cancer	0.000376	0.00471	CbGeAlD
Regorafenib—Neutropenia—Temozolomide—brain cancer	0.000375	0.0048	CcSEcCtD
Regorafenib—Infection—Procarbazine—brain cancer	0.000375	0.0048	CcSEcCtD
Regorafenib—RAF1—spinal cord—brain cancer	0.000373	0.00468	CbGeAlD
Regorafenib—Angiopathy—Hydroxyurea—brain cancer	0.000373	0.00477	CcSEcCtD
Regorafenib—Thrombocytopenia—Procarbazine—brain cancer	0.000369	0.00473	CcSEcCtD
Regorafenib—KDR—pituitary gland—brain cancer	0.000369	0.00463	CbGeAlD
Regorafenib—FGFR2—endocrine gland—brain cancer	0.000365	0.00457	CbGeAlD
Regorafenib—Alopecia—Hydroxyurea—brain cancer	0.000363	0.00465	CcSEcCtD
Regorafenib—Weight decreased—Temozolomide—brain cancer	0.000363	0.00465	CcSEcCtD
Regorafenib—BRAF—brain—brain cancer	0.000361	0.00453	CbGeAlD
Regorafenib—Stomatitis—Carmustine—brain cancer	0.00036	0.00462	CcSEcCtD
Regorafenib—FGFR2—head—brain cancer	0.00036	0.00451	CbGeAlD
Regorafenib—EPHA2—endocrine gland—brain cancer	0.000358	0.00449	CbGeAlD
Regorafenib—Infestation NOS—Temozolomide—brain cancer	0.000357	0.00458	CcSEcCtD
Regorafenib—Infestation—Temozolomide—brain cancer	0.000357	0.00458	CcSEcCtD
Regorafenib—KDR—medulla oblongata—brain cancer	0.000356	0.00446	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.000354	0.00454	CcSEcCtD
Regorafenib—EPHA2—head—brain cancer	0.000354	0.00444	CbGeAlD
Regorafenib—Nausea—Lomustine—brain cancer	0.000353	0.00452	CcSEcCtD
Regorafenib—PDGFRA—spinal cord—brain cancer	0.000352	0.00441	CbGeAlD
Regorafenib—TEK—endocrine gland—brain cancer	0.00035	0.00438	CbGeAlD
Regorafenib—ABL1—telencephalon—brain cancer	0.00035	0.00438	CbGeAlD
Regorafenib—Stomatitis—Temozolomide—brain cancer	0.000348	0.00446	CcSEcCtD
Regorafenib—RET—central nervous system—brain cancer	0.000346	0.00434	CbGeAlD
Regorafenib—TEK—head—brain cancer	0.000345	0.00433	CbGeAlD
Regorafenib—EPHX2—brain—brain cancer	0.000345	0.00432	CbGeAlD
Regorafenib—RET—cerebellum—brain cancer	0.000338	0.00424	CbGeAlD
Regorafenib—FLT1—endocrine gland—brain cancer	0.000338	0.00424	CbGeAlD
Regorafenib—Hepatobiliary disease—Temozolomide—brain cancer	0.000338	0.00433	CcSEcCtD
Regorafenib—RAF1—endocrine gland—brain cancer	0.000336	0.00421	CbGeAlD
Regorafenib—KIT—gonad—brain cancer	0.000335	0.0042	CbGeAlD
Regorafenib—Toxic epidermal necrolysis—Etoposide—brain cancer	0.000334	0.00428	CcSEcCtD
Regorafenib—FLT1—head—brain cancer	0.000334	0.00419	CbGeAlD
Regorafenib—Haemoglobin—Carmustine—brain cancer	0.000334	0.00428	CcSEcCtD
Regorafenib—Haemorrhage—Carmustine—brain cancer	0.000332	0.00425	CcSEcCtD
Regorafenib—RAF1—head—brain cancer	0.000332	0.00416	CbGeAlD
Regorafenib—Anaemia—Hydroxyurea—brain cancer	0.00033	0.00423	CcSEcCtD
Regorafenib—FGFR2—central nervous system—brain cancer	0.000329	0.00412	CbGeAlD
Regorafenib—Decreased appetite—Procarbazine—brain cancer	0.000328	0.0042	CcSEcCtD
Regorafenib—PDGFRB—gonad—brain cancer	0.000327	0.0041	CbGeAlD
Regorafenib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000327	0.00419	CcSEcCtD
Regorafenib—KIT—pituitary gland—brain cancer	0.000327	0.0041	CbGeAlD
Regorafenib—Connective tissue disorder—Carmustine—brain cancer	0.000326	0.00418	CcSEcCtD
Regorafenib—KDR—midbrain—brain cancer	0.000325	0.00408	CbGeAlD
Regorafenib—Fatigue—Procarbazine—brain cancer	0.000325	0.00416	CcSEcCtD
Regorafenib—EPHA2—central nervous system—brain cancer	0.000323	0.00405	CbGeAlD
Regorafenib—Haemoglobin—Temozolomide—brain cancer	0.000322	0.00413	CcSEcCtD
Regorafenib—Pain—Procarbazine—brain cancer	0.000322	0.00413	CcSEcCtD
Regorafenib—FGFR2—cerebellum—brain cancer	0.000321	0.00403	CbGeAlD
Regorafenib—Haemorrhage—Temozolomide—brain cancer	0.000321	0.00411	CcSEcCtD
Regorafenib—Leukopenia—Hydroxyurea—brain cancer	0.00032	0.0041	CcSEcCtD
Regorafenib—PDGFRB—pituitary gland—brain cancer	0.000319	0.004	CbGeAlD
Regorafenib—KDR—spinal cord—brain cancer	0.000317	0.00398	CbGeAlD
Regorafenib—Urinary tract disorder—Temozolomide—brain cancer	0.000317	0.00406	CcSEcCtD
Regorafenib—PDGFRA—endocrine gland—brain cancer	0.000317	0.00397	CbGeAlD
Regorafenib—KIT—medulla oblongata—brain cancer	0.000315	0.00396	CbGeAlD
Regorafenib—Connective tissue disorder—Temozolomide—brain cancer	0.000315	0.00404	CcSEcCtD
Regorafenib—TEK—central nervous system—brain cancer	0.000315	0.00395	CbGeAlD
Regorafenib—Urethral disorder—Temozolomide—brain cancer	0.000314	0.00403	CcSEcCtD
Regorafenib—PDGFRA—head—brain cancer	0.000313	0.00392	CbGeAlD
Regorafenib—FLT4—brain—brain cancer	0.000311	0.0039	CbGeAlD
Regorafenib—Gastrointestinal pain—Procarbazine—brain cancer	0.000308	0.00395	CcSEcCtD
Regorafenib—PDGFRB—medulla oblongata—brain cancer	0.000308	0.00386	CbGeAlD
Regorafenib—TEK—cerebellum—brain cancer	0.000308	0.00386	CbGeAlD
Regorafenib—FGFR1—brain—brain cancer	0.000307	0.00385	CbGeAlD
Regorafenib—FLT1—central nervous system—brain cancer	0.000305	0.00382	CbGeAlD
Regorafenib—Erythema multiforme—Temozolomide—brain cancer	0.000303	0.00389	CcSEcCtD
Regorafenib—RAF1—central nervous system—brain cancer	0.000303	0.0038	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000302	0.00387	CcSEcCtD
Regorafenib—UGT1A1—endocrine gland—brain cancer	0.000302	0.00379	CbGeAlD
Regorafenib—Neutropenia—Etoposide—brain cancer	0.0003	0.00384	CcSEcCtD
Regorafenib—Abdominal pain—Procarbazine—brain cancer	0.000298	0.00382	CcSEcCtD
Regorafenib—Body temperature increased—Procarbazine—brain cancer	0.000298	0.00382	CcSEcCtD
Regorafenib—FLT1—cerebellum—brain cancer	0.000298	0.00373	CbGeAlD
Regorafenib—Cardiac disorder—Temozolomide—brain cancer	0.000298	0.00382	CcSEcCtD
Regorafenib—RAF1—cerebellum—brain cancer	0.000296	0.00371	CbGeAlD
Regorafenib—Alopecia—Carmustine—brain cancer	0.000293	0.00376	CcSEcCtD
Regorafenib—ABL1—gonad—brain cancer	0.000292	0.00366	CbGeAlD
Regorafenib—Angiopathy—Temozolomide—brain cancer	0.000291	0.00373	CcSEcCtD
Regorafenib—Infection—Hydroxyurea—brain cancer	0.00029	0.00371	CcSEcCtD
Regorafenib—Mediastinal disorder—Temozolomide—brain cancer	0.000289	0.0037	CcSEcCtD
Regorafenib—Malnutrition—Carmustine—brain cancer	0.000289	0.0037	CcSEcCtD
Regorafenib—KIT—midbrain—brain cancer	0.000288	0.00362	CbGeAlD
Regorafenib—Nervous system disorder—Hydroxyurea—brain cancer	0.000286	0.00367	CcSEcCtD
Regorafenib—Infestation—Etoposide—brain cancer	0.000286	0.00366	CcSEcCtD
Regorafenib—Infestation NOS—Etoposide—brain cancer	0.000286	0.00366	CcSEcCtD
Regorafenib—KDR—endocrine gland—brain cancer	0.000286	0.00358	CbGeAlD
Regorafenib—Thrombocytopenia—Hydroxyurea—brain cancer	0.000286	0.00366	CcSEcCtD
Regorafenib—PDGFRA—central nervous system—brain cancer	0.000285	0.00358	CbGeAlD
Regorafenib—ABL1—pituitary gland—brain cancer	0.000285	0.00357	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000284	0.00363	CcSEcCtD
Regorafenib—Alopecia—Temozolomide—brain cancer	0.000284	0.00363	CcSEcCtD
Regorafenib—Skin disorder—Hydroxyurea—brain cancer	0.000283	0.00363	CcSEcCtD
Regorafenib—KDR—head—brain cancer	0.000282	0.00354	CbGeAlD
Regorafenib—Acute coronary syndrome—Etoposide—brain cancer	0.000282	0.00361	CcSEcCtD
Regorafenib—PDGFRB—midbrain—brain cancer	0.000282	0.00353	CbGeAlD
Regorafenib—KIT—spinal cord—brain cancer	0.000281	0.00353	CbGeAlD
Regorafenib—Myocardial infarction—Etoposide—brain cancer	0.00028	0.00359	CcSEcCtD
Regorafenib—Malnutrition—Temozolomide—brain cancer	0.000279	0.00358	CcSEcCtD
Regorafenib—PDGFRA—cerebellum—brain cancer	0.000279	0.0035	CbGeAlD
Regorafenib—Stomatitis—Etoposide—brain cancer	0.000279	0.00357	CcSEcCtD
Regorafenib—PDGFRB—spinal cord—brain cancer	0.000275	0.00345	CbGeAlD
Regorafenib—ABL1—medulla oblongata—brain cancer	0.000275	0.00344	CbGeAlD
Regorafenib—RET—brain—brain cancer	0.000275	0.00344	CbGeAlD
Regorafenib—Tremor—Carmustine—brain cancer	0.000271	0.00347	CcSEcCtD
Regorafenib—Asthenia—Procarbazine—brain cancer	0.00027	0.00347	CcSEcCtD
Regorafenib—Hepatobiliary disease—Etoposide—brain cancer	0.00027	0.00347	CcSEcCtD
Regorafenib—Anaemia—Carmustine—brain cancer	0.000267	0.00342	CcSEcCtD
Regorafenib—Tremor—Temozolomide—brain cancer	0.000262	0.00335	CcSEcCtD
Regorafenib—FGFR2—brain—brain cancer	0.000261	0.00327	CbGeAlD
Regorafenib—Leukopenia—Carmustine—brain cancer	0.000259	0.00331	CcSEcCtD
Regorafenib—Anaemia—Temozolomide—brain cancer	0.000258	0.00331	CcSEcCtD
Regorafenib—Diarrhoea—Procarbazine—brain cancer	0.000258	0.00331	CcSEcCtD
Regorafenib—KDR—central nervous system—brain cancer	0.000258	0.00323	CbGeAlD
Regorafenib—EPHA2—brain—brain cancer	0.000256	0.00322	CbGeAlD
Regorafenib—Decreased appetite—Hydroxyurea—brain cancer	0.000254	0.00325	CcSEcCtD
Regorafenib—Urinary tract disorder—Etoposide—brain cancer	0.000254	0.00325	CcSEcCtD
Regorafenib—KIT—endocrine gland—brain cancer	0.000253	0.00318	CbGeAlD
Regorafenib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000252	0.00323	CcSEcCtD
Regorafenib—KDR—cerebellum—brain cancer	0.000252	0.00316	CbGeAlD
Regorafenib—Urethral disorder—Etoposide—brain cancer	0.000252	0.00322	CcSEcCtD
Regorafenib—Fatigue—Hydroxyurea—brain cancer	0.000252	0.00322	CcSEcCtD
Regorafenib—ABL1—midbrain—brain cancer	0.000251	0.00315	CbGeAlD
Regorafenib—TEK—brain—brain cancer	0.00025	0.00314	CbGeAlD
Regorafenib—KIT—head—brain cancer	0.00025	0.00314	CbGeAlD
Regorafenib—Leukopenia—Temozolomide—brain cancer	0.00025	0.0032	CcSEcCtD
Regorafenib—Hypertension—Carmustine—brain cancer	0.00025	0.0032	CcSEcCtD
Regorafenib—Pain—Hydroxyurea—brain cancer	0.00025	0.0032	CcSEcCtD
Regorafenib—PDGFRB—endocrine gland—brain cancer	0.000247	0.0031	CbGeAlD
Regorafenib—ABL1—spinal cord—brain cancer	0.000245	0.00307	CbGeAlD
Regorafenib—PDGFRB—head—brain cancer	0.000244	0.00306	CbGeAlD
Regorafenib—Erythema multiforme—Etoposide—brain cancer	0.000243	0.00311	CcSEcCtD
Regorafenib—FLT1—brain—brain cancer	0.000242	0.00303	CbGeAlD
Regorafenib—Hypertension—Temozolomide—brain cancer	0.000241	0.00309	CcSEcCtD
Regorafenib—RAF1—brain—brain cancer	0.00024	0.00302	CbGeAlD
Regorafenib—Vomiting—Procarbazine—brain cancer	0.00024	0.00307	CcSEcCtD
Regorafenib—Cardiac disorder—Etoposide—brain cancer	0.000238	0.00305	CcSEcCtD
Regorafenib—Rash—Procarbazine—brain cancer	0.000238	0.00305	CcSEcCtD
Regorafenib—Dermatitis—Procarbazine—brain cancer	0.000237	0.00304	CcSEcCtD
Regorafenib—Headache—Procarbazine—brain cancer	0.000236	0.00303	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000236	0.00303	CcSEcCtD
Regorafenib—Infection—Carmustine—brain cancer	0.000234	0.003	CcSEcCtD
Regorafenib—Angiopathy—Etoposide—brain cancer	0.000233	0.00298	CcSEcCtD
Regorafenib—Dry mouth—Temozolomide—brain cancer	0.000233	0.00298	CcSEcCtD
Regorafenib—Mediastinal disorder—Etoposide—brain cancer	0.000231	0.00296	CcSEcCtD
Regorafenib—Thrombocytopenia—Carmustine—brain cancer	0.000231	0.00296	CcSEcCtD
Regorafenib—Body temperature increased—Hydroxyurea—brain cancer	0.000231	0.00296	CcSEcCtD
Regorafenib—KIT—central nervous system—brain cancer	0.000228	0.00286	CbGeAlD
Regorafenib—Alopecia—Etoposide—brain cancer	0.000227	0.00291	CcSEcCtD
Regorafenib—PDGFRA—brain—brain cancer	0.000227	0.00284	CbGeAlD
Regorafenib—Infection—Temozolomide—brain cancer	0.000226	0.0029	CcSEcCtD
Regorafenib—ABCB1—blood vessel—brain cancer	0.000224	0.00281	CbGeAlD
Regorafenib—Nausea—Procarbazine—brain cancer	0.000224	0.00287	CcSEcCtD
Regorafenib—Nervous system disorder—Temozolomide—brain cancer	0.000224	0.00286	CcSEcCtD
Regorafenib—Thrombocytopenia—Temozolomide—brain cancer	0.000223	0.00286	CcSEcCtD
Regorafenib—KIT—cerebellum—brain cancer	0.000223	0.0028	CbGeAlD
Regorafenib—PDGFRB—central nervous system—brain cancer	0.000223	0.00279	CbGeAlD
Regorafenib—Skin disorder—Temozolomide—brain cancer	0.000221	0.00284	CcSEcCtD
Regorafenib—ABL1—endocrine gland—brain cancer	0.00022	0.00276	CbGeAlD
Regorafenib—ABCG2—telencephalon—brain cancer	0.00022	0.00276	CbGeAlD
Regorafenib—PDGFRB—cerebellum—brain cancer	0.000218	0.00273	CbGeAlD
Regorafenib—ABL1—head—brain cancer	0.000218	0.00273	CbGeAlD
Regorafenib—Asthenia—Hydroxyurea—brain cancer	0.000209	0.00268	CcSEcCtD
Regorafenib—Anaemia—Etoposide—brain cancer	0.000207	0.00265	CcSEcCtD
Regorafenib—Decreased appetite—Carmustine—brain cancer	0.000205	0.00263	CcSEcCtD
Regorafenib—KDR—brain—brain cancer	0.000204	0.00256	CbGeAlD
Regorafenib—Gastrointestinal disorder—Carmustine—brain cancer	0.000204	0.00261	CcSEcCtD
Regorafenib—Pain—Carmustine—brain cancer	0.000202	0.00258	CcSEcCtD
Regorafenib—Leukopenia—Etoposide—brain cancer	0.0002	0.00256	CcSEcCtD
Regorafenib—Diarrhoea—Hydroxyurea—brain cancer	0.0002	0.00256	CcSEcCtD
Regorafenib—ABL1—central nervous system—brain cancer	0.000199	0.00249	CbGeAlD
Regorafenib—Decreased appetite—Temozolomide—brain cancer	0.000198	0.00254	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Temozolomide—brain cancer	0.000197	0.00252	CcSEcCtD
Regorafenib—Fatigue—Temozolomide—brain cancer	0.000197	0.00252	CcSEcCtD
Regorafenib—Pain—Temozolomide—brain cancer	0.000195	0.0025	CcSEcCtD
Regorafenib—ABL1—cerebellum—brain cancer	0.000194	0.00243	CbGeAlD
Regorafenib—Hypertension—Etoposide—brain cancer	0.000193	0.00247	CcSEcCtD
Regorafenib—Gastrointestinal pain—Carmustine—brain cancer	0.000193	0.00247	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000189	0.00242	CcSEcCtD
Regorafenib—Abdominal pain—Carmustine—brain cancer	0.000186	0.00239	CcSEcCtD
Regorafenib—Body temperature increased—Carmustine—brain cancer	0.000186	0.00239	CcSEcCtD
Regorafenib—Gastrointestinal pain—Temozolomide—brain cancer	0.000186	0.00239	CcSEcCtD
Regorafenib—Vomiting—Hydroxyurea—brain cancer	0.000186	0.00238	CcSEcCtD
Regorafenib—CYP2C8—pituitary gland—brain cancer	0.000185	0.00231	CbGeAlD
Regorafenib—Rash—Hydroxyurea—brain cancer	0.000184	0.00236	CcSEcCtD
Regorafenib—Dermatitis—Hydroxyurea—brain cancer	0.000184	0.00236	CcSEcCtD
Regorafenib—Headache—Hydroxyurea—brain cancer	0.000183	0.00234	CcSEcCtD
Regorafenib—Infection—Etoposide—brain cancer	0.000181	0.00232	CcSEcCtD
Regorafenib—KIT—brain—brain cancer	0.000181	0.00227	CbGeAlD
Regorafenib—Body temperature increased—Temozolomide—brain cancer	0.00018	0.00231	CcSEcCtD
Regorafenib—Abdominal pain—Temozolomide—brain cancer	0.00018	0.00231	CcSEcCtD
Regorafenib—ABCG2—pituitary gland—brain cancer	0.000179	0.00225	CbGeAlD
Regorafenib—Thrombocytopenia—Etoposide—brain cancer	0.000179	0.00229	CcSEcCtD
Regorafenib—Skin disorder—Etoposide—brain cancer	0.000177	0.00227	CcSEcCtD
Regorafenib—PDGFRB—brain—brain cancer	0.000177	0.00222	CbGeAlD
Regorafenib—Nausea—Hydroxyurea—brain cancer	0.000173	0.00222	CcSEcCtD
Regorafenib—ABCG2—medulla oblongata—brain cancer	0.000173	0.00217	CbGeAlD
Regorafenib—CYP2B6—gonad—brain cancer	0.00017	0.00213	CbGeAlD
Regorafenib—Asthenia—Carmustine—brain cancer	0.000169	0.00217	CcSEcCtD
Regorafenib—CYP2C19—endocrine gland—brain cancer	0.000164	0.00205	CbGeAlD
Regorafenib—Asthenia—Temozolomide—brain cancer	0.000164	0.0021	CcSEcCtD
Regorafenib—Diarrhoea—Carmustine—brain cancer	0.000161	0.00207	CcSEcCtD
Regorafenib—Decreased appetite—Etoposide—brain cancer	0.000159	0.00203	CcSEcCtD
Regorafenib—ABCG2—midbrain—brain cancer	0.000158	0.00198	CbGeAlD
Regorafenib—ABL1—brain—brain cancer	0.000158	0.00198	CbGeAlD
Regorafenib—Gastrointestinal disorder—Etoposide—brain cancer	0.000157	0.00202	CcSEcCtD
Regorafenib—Fatigue—Etoposide—brain cancer	0.000157	0.00201	CcSEcCtD
Regorafenib—Pain—Etoposide—brain cancer	0.000156	0.002	CcSEcCtD
Regorafenib—Diarrhoea—Temozolomide—brain cancer	0.000156	0.002	CcSEcCtD
Regorafenib—ABCG2—spinal cord—brain cancer	0.000154	0.00194	CbGeAlD
Regorafenib—Vomiting—Carmustine—brain cancer	0.00015	0.00192	CcSEcCtD
Regorafenib—Gastrointestinal pain—Etoposide—brain cancer	0.000149	0.00191	CcSEcCtD
Regorafenib—Rash—Carmustine—brain cancer	0.000149	0.00191	CcSEcCtD
Regorafenib—Dermatitis—Carmustine—brain cancer	0.000149	0.0019	CcSEcCtD
Regorafenib—Headache—Carmustine—brain cancer	0.000148	0.00189	CcSEcCtD
Regorafenib—Vomiting—Temozolomide—brain cancer	0.000145	0.00186	CcSEcCtD
Regorafenib—Body temperature increased—Etoposide—brain cancer	0.000144	0.00185	CcSEcCtD
Regorafenib—Abdominal pain—Etoposide—brain cancer	0.000144	0.00185	CcSEcCtD
Regorafenib—Rash—Temozolomide—brain cancer	0.000144	0.00184	CcSEcCtD
Regorafenib—Dermatitis—Temozolomide—brain cancer	0.000144	0.00184	CcSEcCtD
Regorafenib—CYP2C8—endocrine gland—brain cancer	0.000143	0.00179	CbGeAlD
Regorafenib—Headache—Temozolomide—brain cancer	0.000143	0.00183	CcSEcCtD
Regorafenib—Nausea—Carmustine—brain cancer	0.00014	0.0018	CcSEcCtD
Regorafenib—Nausea—Temozolomide—brain cancer	0.000135	0.00173	CcSEcCtD
Regorafenib—Asthenia—Etoposide—brain cancer	0.000131	0.00168	CcSEcCtD
Regorafenib—CYP2B6—endocrine gland—brain cancer	0.000128	0.00161	CbGeAlD
Regorafenib—CYP2C9—endocrine gland—brain cancer	0.000127	0.00159	CbGeAlD
Regorafenib—CYP2B6—head—brain cancer	0.000127	0.00159	CbGeAlD
Regorafenib—Diarrhoea—Etoposide—brain cancer	0.000125	0.0016	CcSEcCtD
Regorafenib—ABCG2—cerebellum—brain cancer	0.000122	0.00154	CbGeAlD
Regorafenib—Vomiting—Etoposide—brain cancer	0.000116	0.00149	CcSEcCtD
Regorafenib—CYP2B6—central nervous system—brain cancer	0.000116	0.00145	CbGeAlD
Regorafenib—Rash—Etoposide—brain cancer	0.000115	0.00147	CcSEcCtD
Regorafenib—Dermatitis—Etoposide—brain cancer	0.000115	0.00147	CcSEcCtD
Regorafenib—Headache—Etoposide—brain cancer	0.000114	0.00146	CcSEcCtD
Regorafenib—ABCB1—telencephalon—brain cancer	0.000109	0.00136	CbGeAlD
Regorafenib—Nausea—Etoposide—brain cancer	0.000108	0.00139	CcSEcCtD
Regorafenib—CYP2C8—brain—brain cancer	0.000102	0.00128	CbGeAlD
Regorafenib—ABCG2—brain—brain cancer	9.95e-05	0.00125	CbGeAlD
Regorafenib—CYP3A4—endocrine gland—brain cancer	9.69e-05	0.00121	CbGeAlD
Regorafenib—CYP2B6—brain—brain cancer	9.18e-05	0.00115	CbGeAlD
Regorafenib—ABCB1—gonad—brain cancer	9.07e-05	0.00114	CbGeAlD
Regorafenib—ABCB1—pituitary gland—brain cancer	8.85e-05	0.00111	CbGeAlD
Regorafenib—CYP3A4—central nervous system—brain cancer	8.73e-05	0.00109	CbGeAlD
Regorafenib—ABCB1—medulla oblongata—brain cancer	8.54e-05	0.00107	CbGeAlD
Regorafenib—ABCB1—midbrain—brain cancer	7.81e-05	0.000979	CbGeAlD
Regorafenib—ABCB1—spinal cord—brain cancer	7.62e-05	0.000955	CbGeAlD
Regorafenib—ABCB1—endocrine gland—brain cancer	6.86e-05	0.00086	CbGeAlD
Regorafenib—ABCB1—head—brain cancer	6.77e-05	0.000849	CbGeAlD
Regorafenib—ABCB1—central nervous system—brain cancer	6.18e-05	0.000775	CbGeAlD
Regorafenib—ABCB1—cerebellum—brain cancer	6.04e-05	0.000757	CbGeAlD
Regorafenib—ABCB1—brain—brain cancer	4.9e-05	0.000615	CbGeAlD
Regorafenib—PDGFRB—Disease—APC—brain cancer	5.76e-06	3.94e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—IDH1—brain cancer	5.73e-06	3.92e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—RELA—brain cancer	5.72e-06	3.91e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL2—brain cancer	5.71e-06	3.91e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—ERBB2—brain cancer	5.68e-06	3.89e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VAV1—brain cancer	5.67e-06	3.88e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SPP1—brain cancer	5.62e-06	3.85e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—EGFR—brain cancer	5.62e-06	3.85e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SPP1—brain cancer	5.61e-06	3.84e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—IDH1—brain cancer	5.6e-06	3.83e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TP53—brain cancer	5.56e-06	3.8e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—EGFR—brain cancer	5.54e-06	3.79e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CTNNB1—brain cancer	5.52e-06	3.77e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—VEGFA—brain cancer	5.49e-06	3.75e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HES1—brain cancer	5.47e-06	3.74e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IRS2—brain cancer	5.46e-06	3.73e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—STAT3—brain cancer	5.43e-06	3.72e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—RELA—brain cancer	5.43e-06	3.71e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—RELA—brain cancer	5.41e-06	3.7e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—ERBB2—brain cancer	5.39e-06	3.69e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—ERBB2—brain cancer	5.38e-06	3.68e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IRS2—brain cancer	5.36e-06	3.67e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—ERBB2—brain cancer	5.34e-06	3.66e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—APC—brain cancer	5.25e-06	3.59e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PIK3CG—brain cancer	5.25e-06	3.59e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—ERBB2—brain cancer	5.25e-06	3.59e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL2—brain cancer	5.25e-06	3.59e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TP53—brain cancer	5.24e-06	3.59e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.23e-06	3.58e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—IDH1—brain cancer	5.23e-06	3.58e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PDGFRA—brain cancer	5.21e-06	3.56e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—APC—brain cancer	5.2e-06	3.56e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PIK3CG—brain cancer	5.2e-06	3.56e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL2—brain cancer	5.15e-06	3.52e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—EGFR—brain cancer	5.14e-06	3.52e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—APC—brain cancer	5.14e-06	3.51e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IRS2—brain cancer	5.09e-06	3.48e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ENO2—brain cancer	5.08e-06	3.47e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IRS2—brain cancer	5.07e-06	3.47e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CTNNB1—brain cancer	5.06e-06	3.46e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SPP1—brain cancer	5.05e-06	3.46e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MYC—brain cancer	5.05e-06	3.45e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—RELA—brain cancer	5.05e-06	3.45e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—CTNNB1—brain cancer	5.04e-06	3.45e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—ERBB2—brain cancer	5.02e-06	3.43e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—ERBB2—brain cancer	4.98e-06	3.41e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—CTNNB1—brain cancer	4.97e-06	3.4e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—ERBB2—brain cancer	4.97e-06	3.4e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—EGFR—brain cancer	4.94e-06	3.38e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—EGFR—brain cancer	4.94e-06	3.38e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	4.93e-06	3.37e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL2—brain cancer	4.89e-06	3.34e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—RELA—brain cancer	4.88e-06	3.34e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL2—brain cancer	4.88e-06	3.34e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HES1—brain cancer	4.87e-06	3.33e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—ERBB2—brain cancer	4.85e-06	3.32e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—APC—brain cancer	4.82e-06	3.3e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PIK3CG—brain cancer	4.82e-06	3.3e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—STAT3—brain cancer	4.81e-06	3.29e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TP53—brain cancer	4.8e-06	3.28e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—RELA—brain cancer	4.77e-06	3.26e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—RELA—brain cancer	4.75e-06	3.25e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—ERBB2—brain cancer	4.74e-06	3.24e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PIK3CG—brain cancer	4.73e-06	3.24e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—APC—brain cancer	4.73e-06	3.24e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—ERBB2—brain cancer	4.72e-06	3.23e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CTNNB1—brain cancer	4.72e-06	3.23e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2C9—brain cancer	4.71e-06	3.23e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CTNNB1—brain cancer	4.71e-06	3.22e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—CTNNB1—brain cancer	4.68e-06	3.2e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	4.67e-06	3.19e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PDGFRA—brain cancer	4.64e-06	3.17e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—CTNNB1—brain cancer	4.59e-06	3.14e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IRS2—brain cancer	4.57e-06	3.13e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL2—brain cancer	4.55e-06	3.11e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ENO2—brain cancer	4.53e-06	3.1e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SPP1—brain cancer	4.5e-06	3.08e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PIK3CG—brain cancer	4.49e-06	3.07e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—APC—brain cancer	4.49e-06	3.07e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PIK3CG—brain cancer	4.48e-06	3.07e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—APC—brain cancer	4.48e-06	3.07e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—ERBB2—brain cancer	4.48e-06	3.06e-05	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—MYC—brain cancer	4.44e-06	3.04e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CCND1—brain cancer	4.43e-06	3.03e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PIK3CG—brain cancer	4.42e-06	3.03e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ENO2—brain cancer	4.42e-06	3.03e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PIK3CG—brain cancer	4.42e-06	3.03e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—STAT3—brain cancer	4.41e-06	3.02e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—STAT3—brain cancer	4.4e-06	3.01e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL2—brain cancer	4.39e-06	3.01e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CTNNB1—brain cancer	4.39e-06	3e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—EGFR—brain cancer	4.37e-06	2.99e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CTNNB1—brain cancer	4.36e-06	2.98e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—RELA—brain cancer	4.35e-06	2.97e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CTNNB1—brain cancer	4.35e-06	2.97e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—STAT3—brain cancer	4.34e-06	2.97e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—ERBB2—brain cancer	4.32e-06	2.96e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL2—brain cancer	4.3e-06	2.94e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL2—brain cancer	4.29e-06	2.93e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL2—brain cancer	4.28e-06	2.93e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	4.26e-06	2.91e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CTNNB1—brain cancer	4.24e-06	2.9e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CCND1—brain cancer	4.19e-06	2.86e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CTNNB1—brain cancer	4.15e-06	2.84e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—brain cancer	4.15e-06	2.84e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CTNNB1—brain cancer	4.13e-06	2.83e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ENO2—brain cancer	4.13e-06	2.83e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—STAT3—brain cancer	4.11e-06	2.81e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—STAT3—brain cancer	4.1e-06	2.81e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—RELA—brain cancer	4.1e-06	2.81e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—MYC—brain cancer	4.09e-06	2.8e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—ERBB2—brain cancer	4.08e-06	2.79e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—STAT3—brain cancer	4.08e-06	2.79e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IRS2—brain cancer	4.07e-06	2.79e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—RELA—brain cancer	4.06e-06	2.78e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—ERBB2—brain cancer	4.04e-06	2.76e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—APC—brain cancer	4.04e-06	2.76e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PIK3CG—brain cancer	4.04e-06	2.76e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—EGFR—brain cancer	4.01e-06	2.74e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—BSG—brain cancer	4.01e-06	2.74e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—STAT3—brain cancer	4e-06	2.74e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—EGFR—brain cancer	4e-06	2.73e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—ERBB2—brain cancer	3.99e-06	2.73e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—EGFR—brain cancer	3.94e-06	2.7e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL2—brain cancer	3.92e-06	2.68e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CTNNB1—brain cancer	3.92e-06	2.68e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—VEGFA—brain cancer	3.86e-06	2.64e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—STAT3—brain cancer	3.83e-06	2.62e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—STAT3—brain cancer	3.8e-06	2.6e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—STAT3—brain cancer	3.79e-06	2.59e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—MYC—brain cancer	3.79e-06	2.59e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CTNNB1—brain cancer	3.78e-06	2.59e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—RELA—brain cancer	3.77e-06	2.58e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CG—brain cancer	3.75e-06	2.57e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—ERBB2—brain cancer	3.74e-06	2.56e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—EGFR—brain cancer	3.74e-06	2.56e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—EGFR—brain cancer	3.73e-06	2.55e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—MYC—brain cancer	3.72e-06	2.54e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—EGFR—brain cancer	3.7e-06	2.53e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—RELA—brain cancer	3.7e-06	2.53e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—STAT3—brain cancer	3.7e-06	2.53e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL2—brain cancer	3.69e-06	2.53e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—ERBB2—brain cancer	3.68e-06	2.51e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL2—brain cancer	3.66e-06	2.5e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—VEGFA—brain cancer	3.65e-06	2.5e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—EGFR—brain cancer	3.64e-06	2.49e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—STAT3—brain cancer	3.61e-06	2.47e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—STAT3—brain cancer	3.6e-06	2.46e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CCND1—brain cancer	3.6e-06	2.46e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—APC—brain cancer	3.6e-06	2.46e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CG—brain cancer	3.6e-06	2.46e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CCND1—brain cancer	3.57e-06	2.44e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CTNNB1—brain cancer	3.57e-06	2.44e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MYC—brain cancer	3.55e-06	2.43e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CTNNB1—brain cancer	3.53e-06	2.42e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—MYC—brain cancer	3.53e-06	2.41e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—MYC—brain cancer	3.52e-06	2.41e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—RELA—brain cancer	3.51e-06	2.4e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—RELA—brain cancer	3.5e-06	2.39e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CTNNB1—brain cancer	3.49e-06	2.39e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—ERBB2—brain cancer	3.49e-06	2.39e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—ERBB2—brain cancer	3.48e-06	2.38e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—EGFR—brain cancer	3.48e-06	2.38e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—EGFR—brain cancer	3.45e-06	2.36e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—IDH1—brain cancer	3.45e-06	2.36e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—EGFR—brain cancer	3.44e-06	2.36e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—STAT3—brain cancer	3.41e-06	2.34e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL2—brain cancer	3.39e-06	2.32e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—EGFR—brain cancer	3.36e-06	2.3e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MYC—brain cancer	3.36e-06	2.3e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL2—brain cancer	3.33e-06	2.28e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CCND1—brain cancer	3.31e-06	2.26e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—STAT3—brain cancer	3.3e-06	2.25e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—EGFR—brain cancer	3.29e-06	2.25e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—EGFR—brain cancer	3.28e-06	2.24e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—EGFR—brain cancer	3.27e-06	2.24e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CTNNB1—brain cancer	3.27e-06	2.24e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CCND1—brain cancer	3.25e-06	2.22e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CTNNB1—brain cancer	3.22e-06	2.2e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MYC—brain cancer	3.17e-06	2.17e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL2—brain cancer	3.16e-06	2.16e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—RELA—brain cancer	3.15e-06	2.16e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL2—brain cancer	3.15e-06	2.16e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—VEGFA—brain cancer	3.14e-06	2.15e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—ERBB2—brain cancer	3.13e-06	2.14e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—brain cancer	3.11e-06	2.13e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—STAT3—brain cancer	3.11e-06	2.13e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—EGFR—brain cancer	3.1e-06	2.12e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCND1—brain cancer	3.08e-06	2.11e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—STAT3—brain cancer	3.08e-06	2.11e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCND1—brain cancer	3.07e-06	2.1e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CTNNB1—brain cancer	3.05e-06	2.09e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CTNNB1—brain cancer	3.04e-06	2.08e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—STAT3—brain cancer	3.04e-06	2.08e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—EGFR—brain cancer	2.99e-06	2.05e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—brain cancer	2.92e-06	2e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MYC—brain cancer	2.89e-06	1.98e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—brain cancer	2.88e-06	1.97e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MYC—brain cancer	2.86e-06	1.96e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—STAT3—brain cancer	2.85e-06	1.95e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2—brain cancer	2.84e-06	1.94e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—brain cancer	2.83e-06	1.94e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MYC—brain cancer	2.83e-06	1.93e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EGFR—brain cancer	2.83e-06	1.93e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—RELA—brain cancer	2.81e-06	1.92e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—STAT3—brain cancer	2.8e-06	1.92e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EGFR—brain cancer	2.8e-06	1.91e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ERBB2—brain cancer	2.79e-06	1.91e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCND1—brain cancer	2.77e-06	1.89e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—EGFR—brain cancer	2.77e-06	1.89e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—brain cancer	2.76e-06	1.89e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CG—brain cancer	2.75e-06	1.88e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CTNNB1—brain cancer	2.74e-06	1.88e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO2—brain cancer	2.72e-06	1.86e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—brain cancer	2.69e-06	1.84e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—brain cancer	2.68e-06	1.83e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—brain cancer	2.66e-06	1.82e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—brain cancer	2.65e-06	1.82e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—brain cancer	2.65e-06	1.81e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—brain cancer	2.6e-06	1.78e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—brain cancer	2.59e-06	1.77e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—brain cancer	2.55e-06	1.74e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—brain cancer	2.53e-06	1.73e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—brain cancer	2.47e-06	1.69e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCND1—brain cancer	2.47e-06	1.69e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—brain cancer	2.47e-06	1.69e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CTNNB1—brain cancer	2.44e-06	1.67e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—brain cancer	2.42e-06	1.65e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—brain cancer	2.41e-06	1.65e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—brain cancer	2.41e-06	1.65e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—brain cancer	2.39e-06	1.64e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—brain cancer	2.37e-06	1.62e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—brain cancer	2.35e-06	1.61e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CG—brain cancer	2.33e-06	1.59e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—brain cancer	2.22e-06	1.52e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—brain cancer	2.18e-06	1.49e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—brain cancer	2.17e-06	1.49e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—brain cancer	2.15e-06	1.47e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—brain cancer	2.14e-06	1.46e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—brain cancer	2.13e-06	1.46e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CG—brain cancer	2.08e-06	1.42e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—brain cancer	2.03e-06	1.39e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CG—brain cancer	2.03e-06	1.39e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—brain cancer	2.02e-06	1.39e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—brain cancer	1.98e-06	1.35e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—brain cancer	1.94e-06	1.32e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CG—brain cancer	1.9e-06	1.3e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—brain cancer	1.82e-06	1.25e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—brain cancer	1.63e-06	1.11e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CG—brain cancer	1.25e-06	8.55e-06	CbGpPWpGaD
